国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

美國CardioMEMS
CardioMEMS是一個(gè)醫療器械公司已開(kāi)發(fā)并正在商業(yè)化專(zhuān)有無(wú)線(xiàn)傳感和人體通信技術(shù)。我們的技術(shù)平臺，目的是改善諸如動(dòng)脈瘤，心臟衰竭，高血壓，嚴重慢性心血管疾病的管理。我們的微型無(wú)線(xiàn)傳感器可以植入用微創(chuàng )技術(shù)和傳輸心輸出量，血壓和心率數據，是至關(guān)重要的病人管理。我們的傳感器被設計成永久性心臟和血管由于其體積小，耐用性植入，以及電線(xiàn)和電池不足。利用射頻或RF，能源，我們的傳感器傳送實(shí)時(shí)數據外部電子閱讀器，然后傳達這一信息對病人的醫生。我們相信頻繁，點(diǎn)播，重要信息的實(shí)時(shí)監測病人能夠主動(dòng)管理，持有減少住院的承諾，改善病人的生活質(zhì)量和提供更有效率和成本效益的醫療。
所作的發(fā)言，本新聞稿中期待在時(shí)間或表達信念，預期或對未來(lái)的希望或預期出現的結果都是前瞻性聲明。阿如產(chǎn)品開(kāi)發(fā)和商業(yè)化的努力預計何時(shí)或任何臨床試驗，最終的臨床結果和知覺(jué)或本公司的產(chǎn)品，市場(chǎng)和醫生的產(chǎn)品，知識產(chǎn)權保護驗收的實(shí)際優(yōu)勢的結果，可能帶來(lái)的風(fēng)險的風(fēng)險和不確定性和競爭產(chǎn)品可能導致實(shí)際事件產(chǎn)生不利不同的期望表示在這些前瞻性聲明。
CardioMEMS是CardioMEMS，公司的注冊商標

美國CardioMEMS公司最近成功融資兩千兩百一十萬(wàn)美元，用于重要的臨床試驗。CardioMEMS正在開(kāi)發(fā)一種能夠植入人體來(lái)控制心力衰竭、動(dòng)脈瘤、高血壓等嚴重的慢性心血管疾病的無(wú)線(xiàn)器件。以上投資來(lái)自公司現有的投資者，包括Arcapita Ventures、Boston Millennia Partners、 Foundation Medical Partners，是其計劃的二千九百五十五萬(wàn)元融資的一部分。

資金將用于CHAMPION臨床試驗，評估CardioMEMS心力衰竭壓力監控系統。臨床試驗將在美國的65個(gè)心血管中心進(jìn)行。

CardioMEMS的心力衰竭傳感器是一個(gè)微型器件，將用導管的方式植入肺動(dòng)脈。肺動(dòng)脈的壓力則利用公司的專(zhuān)利電子監控系統測量并顯示。遵照程序，病人在家里無(wú)線(xiàn)監測其肺動(dòng)脈壓力，數據立即傳送到安全的數據庫，供醫生通過(guò)CardioMEMS的網(wǎng)站實(shí)時(shí)監測。

CardioMEMS預期在2010年尋求FDA對其CHAMPION心力衰竭傳感器的認證。

在2007年，CardioMEMS融資三千三百萬(wàn)美元。

CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Our miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients. Due to their small size, durability, and lack of wires and batteries, our sensors are designed to be permanently implanted into the cardiovascular system. Using radiofrequency, or RF, energy, our sensors transmit real-time data to an external electronics module, which then communicates this information to the patient’s physician.

Our first commercial device, the EndoSure? Wireless AAA Pressure Measurement System, is comprised of an implanted sensor and an external electronics module. The EndoSure? sensor is inserted during the minimally invasive endovascular repair of abdominal aortic aneurysms, or AAA, via a catheter into a patient’s aneurysm sac and measures and communicates pressure information to an external electronics module from inside the sac. We are adapting the technology used for our EndoSure? system for use in patients with heart failure and in patients with hypertension. Our heart failure and hypertension sensors will be further miniaturized versions of the EndoSure? sensor that use the same materials, manufacturing methods and operational concepts as the EndoSure? sensor.